QGEN Price Prediction Next Week
Analysis and Insights
Technical Analysis:
QGEN's stock is currently trading at $39.37, near the lower end of its 52-week range ($38.14 - $47.93). The Relative Strength Index (RSI) is at 44.06, indicating the stock is not in oversold territory but is approaching it. The MACD is slightly negative, suggesting bearish momentum, but it is close to crossing over, which could signal a potential reversal.
News Impact:
NIH Funding Cuts: The NIH's announcement of funding cuts led to a decline in QGEN's stock price. However, a preliminary injunction has been issued, which may provide some relief to life sciences companies, including QGEN.
Patent Infringement Complaint: QGEN has filed a complaint against bioMérieux S.A. to protect its QuantiFERON technology, which could have a positive impact on investor sentiment.
Fibonacci Levels:
The Fibonacci levels for QGEN are as follows:
- R1: $39.87
- S1: $37.96
- Pivot: $38.91
The stock is currently trading near the pivot level, with resistance at $39.87 and support at $37.96.
Price Prediction:
Based on the technical indicators and news sentiment, QGEN's stock is expected to trade in a narrow range next week. The stock may face resistance at $39.87 and support at $38.14.
Predicted Price Range: $38.50 - $40.00
Recommendation:
Given the current technical indicators and news sentiment, it is recommended to sell QGEN if the stock approaches the upper end of the predicted range ($40.00). The stock may struggle to break above this level due to resistance and mixed market sentiment.
QGEN Similar Chart Price Prediction
The price of QGEN is predicted to go up -3.67%, based on the high correlation periods with HOV. The similarity of these two price pattern on the periods is 98.45%.
QGEN
HOV
Down: -3.67%Similarity: 98.45%
QGEN Revenue Forecast
QGEN EPS Forecast
QGEN FAQs
What is QGEN revenue forecast for next quarter？
What is QGEN eps forecast for next quarter？
QGEN VS S&P500
Qiagen's long-term growth prospects in the life science and diagnostic markets will not dissolve just because the pandemic turns into an endemic situation.
Qiagen aims to expand its infectious disease platform with a variety of new instrument and test menu introductions, which should support strong growth in the long run.
With its QuantiFERON technology, Qiagen aims to grow in large market opportunities like TB and lyme disease.
QGEN Analyst's Forecast
Catherine Schulte
Baird
Buy → Hold
2025-02-19
Price Target
$52 → $42
Upside
+7.09%
Baird downgraded Qiagen to Neutral from Outperform with a price target of $42, down from $52. The firm has concerns around the future of National Institutes of Health funding, particularly after surveying academic researchers last week. Given these uncertainties and sentiment overhang, it downgrades the shares. While the stock has pulled back significantly since the Trump inauguration, Baird has "trouble seeing what gets sentiment working again absent some sort of resolution," the analyst tells investors in a research note.
Steve Beuchaw
Morgan Stanley
Buy → Hold
2025-01-06
Price Target
$50 → $48
Upside
+6.81%
Tycho Peterson
Jefferies
Hold → Strong Buy
2024-12-10
Price Target
$42 → $54
Upside
+16.98%
